Cogent Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-328.9M | $-255.9M | $-192.4M | $-140.2M | $-72.3M | $-74.8M | $-31.8M | $-34.5M |
| Depreciation & Amortization | $2.6M | $2.5M | $2.3M | $800.0K | $147.0K | $720.0K | $1.3M | $1.3M |
| Depreciation | $2.6M | $2.5M | $2.3M | $842.0K | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $46.1M | $39.7M | $30.6M | $18.4M | $11.7M | $6.0M | $3.2M | $3.1M |
| Net Cash from Operating Activities | $-264.4M | $-207.8M | $-153.6M | $-118.6M | $-58.8M | $-35.9M | $-41.5M | $-32.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.6M | $573.0K | $2.8M | $6.9M | $1.7M | — | $33.0K | $549.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-399.5M | $38.3M | $-97.8M | $-124.7M | $-1.7M | $8.4M | $23.2M | $-10.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $878.2M | $214.5M | $163.5M | $163.6M | $38.0M | $232.2M | $108.0K | $70.3M |
| Net Change in Cash | $214.3M | $44.9M | $-87.9M | $-79.8M | $-22.5M | $204.8M | $-18.2M | $27.3M |
| Free Cash Flow | $-266.0M | $-208.4M | $-156.4M | $-125.5M | $-60.5M | — | $-41.5M | $-33.0M |